Telix Pharmaceuticals (ASX: TLX) has announced its financial results for the year ending December 31, 2022, reporting the group revenue was $160.1M (2021: $7.6M) as a result of the commercial launch of Illuccix®.
Telix Pharmaceuticals also reported Net loss after tax was $104.1M (2021: $80.5M), and Cash and cash equivalents of $116.3M as at 31 December 2022 (2021: $22.0M).
Adjusted EBITDA was $(67.8)M (2021: $(76.1)M).
The company also says data from Phase III ZIRCON trial of investigational kidney cancer imaging agent TLX250-CDx was highly positive, paving the way to commence regulatory filing process for a second imaging agent for the urology field.